How to buy Phio Pharmaceuticals stock - 07 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Phio Pharmaceuticals stock

Own Phio Pharmaceuticals stock in just a few minutes.

Fact checked

Phio Pharmaceuticals Corp is a biotechnology business based in the US. Phio Pharmaceuticals shares (PHIO) are listed on the NASDAQ and all prices are listed in US Dollars. Phio Pharmaceuticals employs 11 staff and has a market cap (total outstanding shares value) of USD$42.9 million.

How to buy shares in Phio Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Phio Pharmaceuticals. Find the stock by name or ticker symbol: PHIO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Phio Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Phio Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Phio Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Phio Pharmaceuticals share price

Use our graph to track the performance of PHIO stocks over time.

Phio Pharmaceuticals shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$1.6 - USD$4.36
50-day moving average USD$3.2559
200-day moving average USD$2.5721
Wall St. target priceUSD$4
PE ratio 0.1834
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.445

Buy Phio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Phio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Phio Pharmaceuticals under- or over-valued?

Valuing Phio Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Phio Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Phio Pharmaceuticals's P/E ratio

Phio Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Phio Pharmaceuticals shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Phio Pharmaceuticals financials

Gross profit TTM USD$-4,279,000
Return on assets TTM -39.73%
Return on equity TTM -78%
Profit margin 0%
Book value $2.673
Market capitalisation USD$42.9 million

TTM: trailing 12 months

Shorting Phio Pharmaceuticals shares

There are currently 864,242 Phio Pharmaceuticals shares held short by investors – that's known as Phio Pharmaceuticals's "short interest". This figure is 33.2% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting Phio Pharmaceuticals shares can be evaluated.

Phio Pharmaceuticals's "short interest ratio" (SIR)

Phio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Phio Pharmaceuticals shares currently shorted divided by the average quantity of Phio Pharmaceuticals shares traded daily (recently around 1.5 million). Phio Pharmaceuticals's SIR currently stands at 0.57. In other words for every 100,000 Phio Pharmaceuticals shares traded daily on the market, roughly 570 shares are currently held short.

However Phio Pharmaceuticals's short interest can also be evaluated against the total number of Phio Pharmaceuticals shares, or, against the total number of tradable Phio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Phio Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Phio Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.0783% of the tradable shares (for every 100,000 tradable Phio Pharmaceuticals shares, roughly 78 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Phio Pharmaceuticals.

Find out more about how you can short Phio Pharmaceuticals stock.

Phio Pharmaceuticals share dividends

We're not expecting Phio Pharmaceuticals to pay a dividend over the next 12 months.

Have Phio Pharmaceuticals's shares ever split?

Phio Pharmaceuticals's shares were split on a 1:55 basis on 15 January 2020. So if you had owned 55 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Phio Pharmaceuticals shares – just the quantity. However, indirectly, the new 5400% higher share price could have impacted the market appetite for Phio Pharmaceuticals shares which in turn could have impacted Phio Pharmaceuticals's share price.

Phio Pharmaceuticals share price volatility

Over the last 12 months, Phio Pharmaceuticals's shares have ranged in value from as little as $1.6 up to $4.36. A popular way to gauge a stock's volatility is its "beta".

PHIO.US volatility(beta: 2.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Phio Pharmaceuticals's is 2.2375. This would suggest that Phio Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Phio Pharmaceuticals overview

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site